Video

Dr. Azad on the Importance of Germline Testing in CRC

Nilofer S​aba Azad, MD, discusses the significance of germline testing in colorectal cancer.

Nilofer S​aba Azad, MD, associate professor of oncology, Johns Hopkins ​University School of Medicine, ​director, Developmental Therapeutics Clinical Trials Program, Johns Hopkins Sidney Kimmel Cancer Center, discusses the significance of germline testing in colorectal cancer (CRC).

Hereditary nonpolyposis CRC or Lynch syndrome is present in 1% to 2% of patients​, says Azad. However, it is the most common hereditary cancer syndrome and is associated with an increased risk of developing CRC, as well as other cancers.

 ​Notably, broad molecular testing for hereditary syndromes by genetic counselors can result in earlier detection of associated cancers at more treatable stages​, Azad explains.

Despite the rarity of this genetic syndrome, families that have a strong history of cancer, as well as individuals who are diagnosed with CRC under the age of 50, should undergo germline genetic ​testing, Azad concludes.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD